NCT05053152 2026-01-14
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NRG Oncology
Phase 2 Recruiting
Clinical Trials
15 trialsNCT05722925 2025-11-14
Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
OHSU Knight Cancer Institute
Phase 4 Active not recruiting
NCT06062745 2025-11-05
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
Brigham and Women's Hospital
Phase 1 Recruiting
NCT04134208 2025-01-16
An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Phase 4 Terminated
NCT03707184 2024-11-29
Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone
University of Utah
Phase 2 Completed
NCT05035732 2024-01-18
A Prospective Pilot Study for the Evaluation of 18F- Fluciclovine PET/MRI in Radio-recurrent Prostate Cancer (RRPC-PET/MRI Study)
M.D. Anderson Cancer Center
Phase NA Withdrawn
NCT03263780 2021-02-21
High Resolution PET-MRI Before Prostate Cancer HIFU
Cedars-Sinai Medical Center
Phase 2 Completed
NCT03081884 2021-01-25
EDRN-FACBC
Emory University
Phase 2 Completed
NCT03515577 2020-10-14
PSMA vs AXUMIN
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT03264456 2020-03-09
Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI
University of Alabama at Birmingham
Phase 1/2 Completed
NCT02830880 2020-01-07
FACBC Prostate Therapy Response
Emory University
Phase 2 Completed
NCT03996993 2019-06-25
Defining Recurrent Disease With Axuminâ„¢
Cancer Center of Irvine
Unknown
NCT01808222 2019-01-07
FACBC for Recurrent Prostate Cancer
Emory University
Phase 2 Completed
NCT00562315 2016-06-21
FACBC PET/CT for Recurrent Prostate Cancer
Emory University
Phase 2 Completed
NCT00917865 2014-01-07
FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer
Emory University
Phase 2 Terminated